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Background: B cell translocation gene 1 (BTG1) has long been recognized as a tumor suppressor gene. Recent
reports demonstrated that BTG1 plays an important role in progression of cell cycle and is involved in cellular
response to stressors. However, the microRNAs mediated regulatory mechanism of BTG1 expression has not been
reported so far. MicroRNAs can effectively influence tumor radiosensitivity by preventing cell cycle progression,
resulting in enhancement of the cytotoxicity of radiotherapy efficacy. This study aimed to demonstrating the effects
of microRNAs on the BTG1 expression and cellular radiosensitivity.
Methods: The human renal carcinoma 786-O cells were treated with 5 Gy of X-rays. Expressions of BTG1 gene and
miR-454-3p, which was predicted to target BTG1 by software algorithm, were analyzed by quantitative polymerase
chain reaction. Protein expressions were assessed by Western blot. Luciferase assays were used to quantify the
interaction between BTG1 3′-untranslated region (3′-UTR) and miR-454-3p. The radiosensitivity was quantified by
the assay of cell viability, colony formation and caspase-3 activity.
Results: The expression of the BTG1 gene in 786-O cells was significantly elevated after treatments with X-ray
irradiation, DMSO, or serum starvation. The up-regulation of BTG1 after irradiation reduced cellular radiosensitivity as
demonstrated by the enhanced cell viability and colony formation, as well as the repressed caspase-3 activity. In
comparison, knock down of BTG1 by siRNA led to significantly enhanced cellular radiosensitivity. It was found that
miR-454-3p can regulate the expression of BTG1 through a direct interaction with the 3′-UTR of BTG1 mRNA.
Decreasing of its expression level correlates well with BTG1 up-regulation during X-ray irradiation. Particularly, we
observed that over-expression of miR-454-3p by transfection inhibited the BTG1 expression and enhanced the
radiosensitivity. In addition, cell cycle analysis showed that over-expression of miR-454-3p shifted the cell cycle arrest
from G2/M phase to S phase.
Conclusions: Our results indicate that BTG1 is a direct target of miR-454-3p. Down-regulation of BTG1 by miR-454-3p
renders tumor cells sensitive to radiation. These results may shed light on the potential application in tumor radiotherapy.
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Enhancing the radiosensitivity of resistant tumor cells is
a common emphasis in the application of clinical radio-
therapy [1]. Tumor suppressor genes that regulate cell
cycle can alter the radiosensitivity of cancer cells. For ex-
ample, down-regulation of RB1 correlates with increased
apoptosis induced by radiation in human breast cancer* Correspondence: jufangwang@impcas.ac.cn
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unless otherwise stated.cells [2,3]; the mutations in the p53 tumor suppressor
gene enhances the radiosensitivity in oral cavity carcin-
oma cells [4]; and P21 deficiency is associated with a ra-
diosensitive phenotype in colorectal carcinoma cells [5].
The RB1, p53 and p21 are tumor suppressor genes and
play cruical roles in controlling the progression of cell
cycle [6,7]. These findings indicate that cell cycle regula-
tion genes may be intimately related to radiosensitiza-
tion, therefore, could potentially be exploited in tumor
radiotherapy. In this study, the human renal carcinoma. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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resistant [8], was used as experimental model.
B cell translocation gene 1 (BTG1) is another tumor
suppressor gene [9,10]. The BTG1 protein, together with
five additional proteins (BTG2/PC3/Tis21, BTG3/ANA,
BTG4/PC3B, Tob1/Tob, and Tob2), comprise the BTG/
TOB family of anti-proliferative genes involved in the
regulation of cell growth [11]. Expression of BTG1 not
only inhibits the proliferation of cells but also leads to
G1 phase cell cycle arrest in multiple types of cells
[12-14]. Some studies have shown that BTG1 is involved
in the general processes of cell cycle control and in cel-
lular responses to stress [15], though a specific role for
BTG1 in renal cell carcinoma has not been determined.
In consideration of the common physiological function
of tumor suppressor genes in controlling cell cycle, we
propose that BTG1 may have a similar impact as RB1,
p53, and p21 on the radiosensitivity of renal carcinoma
tumor cells.
Certain members of the BTG/TOB family are known
to be regulated by microRNAs (miRNAs) [16], which are
small non-coding RNA molecules that suppress gene ex-
pression via sequence-specific interactions with the 3′-
untranslated region (3′-UTR) of their target transcripts
[17]. For example, BTG2 was shown to be suppressed by
miR-21 [18]; over-expression of miR-142-5p leads to
down-regulation of BTG3 [19]; and TOB2 was shown to
be a target gene of miR-322 [20]. However, miRNA can-
didates that target BTG1 have not been identified.
The strategy of using miRNAs as therapeutic targets to
enhance cellular radiosensitivity has been discussed before
[21]. miRNAs can efficiently modulate tumor radiosen-
sitivity at four aspects containing DNA damage repair,
radio-related signal transduction pathways, tumor micro-
environment and apoptosis [22,23]. Recent reports show
that miRNAs can effectively influence tumor radiosensitiv-
ity by impeding cell cycle progression, resulting in en-
hancement of radiotherapy efficacy [24]. For example,
miR-21 can improve tumor radiosensitivity and promote
apoptosis through negatively regulating the CDC25A ex-
pression and cell cycle progression [25]. Up-regulation of
miR-504 can reduce p53 protein level and affect cell cycle
arrest and radiosensitivity mediated by p53 [26]. With
these precedents, we tested whether the BTG1 could be
regulated by miRNAs upon irradiation and how the cellu-
lar radiosensitivity in renal carcinoma cells could be af-
fected by the changes of miRNAs targeting BTG1.
Methods
Cell culture and irradiation
Human renal carcinoma 786-O cells were cultured in
RPMI-1640 media (GIBCO, NY, USA) supplemented with
10% fetal bovine serum (Hyclone, MA, USA) at 37°C and
5% CO2. Irradiation was carried out by laboratory X-raysource (RX-650, Faxitron Bioptics, USA) [27]. The dose
rate was 0.8 Gy/min (100 keV, 5 mA). Cells were seeded
into 12-well plates and grown to <70% confluence at the
time of irradiation.
Cell cycle assay
Cells were harvested and fixed as described previously [28].
Prior to analysis, fixed cells were washed twice with PBS,
treated with 100 μg/mL RNase A and 50 μg/mL propidium
iodide (BD Biosciences, California, USA) for 20 min, and
analyzed using FACS Calibur flow cytometry (Becton
Dickinson, NJ, USA). Cell cycle distribution was analyzed
with the FlowJo software package. DNA content of sam-
ples was measured with CellQuest (Becton Dickinson).
Western blot analysis
Western blotting was performed as described previously
[29]. Briefly, cells were collected and lysed with RIPA
buffer solution (Beyotime, Haimen, China). Supernatants
were collected at 10,000 g for 10 min at 4°C. The con-
centrations of samples were determined using a BCA
protein assay kit (Pierce, IL, USA). Equal amounts of
protein were loaded onto 10% SDS-polyacrylamide gels
for electrophoresis, and proteins were transferred onto
PVDF membrane by western blotting. GAPDH was used
as loading control. Membranes were then blocked with
nonfat milk and incubated overnight at 4°C with the fol-
lowing primary antibodies: anti-GAPDH (1:5,000, Santa
Cruz), anti-BTG1 (1:1,000, Abnova, Taipei, Taiwan). Im-
munological complexes were detected by enhanced elec-
trochemiluminescence (Millipore, Darmstadt, Germany)
with either an anti-rabbit peroxidase (1:5000, Santa
Cruz, Texas, USA), or an anti-mouse peroxidase (1:4000,
Santa Cruz) antibody. The fold changes of protein levels
were analyzed by the Image J software.
Transfection
MicroRNA mimic and negative control mimic were syn-
thesized and purified by RiboBio Co. (Guangzhou, China)
[29]. Transfections of the miRNA duplexes were per-
formed with 40–60% confluent cells using Lipofectamine
2000 (Invitrogen, California, USA). The medium was re-
placed with new culture medium for 5 h after transfection.
Trypan blue dye exclusion assay
Cell viability is calculated as the number of viable cells
divided by the total number of cells within the grids on
the hemacytometer. Cells which take in trypan blue are
considered non-viable. Cells were harvested with trypsin,
suspended in PBS and mixed with 0.4% solution of try-
pan blue stain (Invitrogen) after various treatments.
Count at least 500 cells for calculation. The percentage
of viable cells = [1.00 - (Number of blue cells/Number of
total cells)]*100%.
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To evaluate the activity of caspase-3, the caspase-3 activ-
ity kit (Beyotime) was used. Cells were collected and
lysed with reaction buffer and the total protein concen-
tration is 1-3 mg/mL. In the samples, activated caspase-
3 cleaves substrate (Ac-DEVD-pNA) (2 mM) between
DEVD and pNA, quantitatively generating pNA that can
be detected using an ELISA reader at an absorbance of
405 nm. In the caspase-3 colorimetric calibration, the
value of R2 should be greater than 0.999.
Colony formation assay
The clonogenic assay was conducted as described previ-
ously [30]. Briefly, cells were harvested and an appropri-
ated number of cells were seeded onto each of the 60 mm
dishes to produce about 50–120 colonies. After 8–10 days
incubation, the colonies were washed with 1 × PBS softly,
fixed with 70% ethanol for 5 min and stained with 0.5%
crystal violet for 3 min at room temperature. Colonies
with more than 50 cells were counted.
Luciferase reporter assay
The 3′-untranslated region (3′-UTR) of human BTG1
transcript was cloned downstream of the luciferase gene
between the Xho I and Sal I sites of the pmirGLO dual-
luciferase vector (Promega, WI, USA). A pmirGLO dual-
luciferase vector containing one mutated seed sequences
of miR-454-3p was constructed. The sequencing of con-
structed plasmids was verified by Shanghai Sangon Bio-
technology Co. (Shanghai, China). 1.5 × 105 786-O cells in
12-well plate were co-transfected with 300 ng DNA (pmir-
GLO-3′ UTR constructs or derived mutants) and 30 nM
of either miR-454-3p mimics using transfection reagent
Lipofectamine 2000 (Invitrogen). Luciferase activity was
measured 48 h later using the Dual Luciferase Reporter
Assay System (Promega) [31] with a Tecan Infinite M200
Pro microplate reader (Tecan, Mannedorf, Switzerland).
Quantitative real-time reverse transcription-PCR
For qRT-PCR, total RNAs were extracted from cultured
cells using TRIzol Reagent (Invitrogen) according to the
manufacturer’s protocol. Reverse transcription and quanti-
tative RT-PCR were performed according to the protocol of
the qRT-PCR Detection Kit (Promega). All of the stem-loop
RT primers were purchased from RiboBio Co. (Guangzhou,
China) to detect miR-454-3p or U6. U6 was used as an en-
dogenous control for miRNAs and GAPDH for coding





and 5′-GGAGGAGTGGGTGTCGCTGT-3′. Gene-specificprimers were synthesized from Shanghai Sangon Biotech-
nology Co. (Shanghai, China).
Statistical analyses
All experiments were repeated at least three times, and
data were presented as means ± SE. The statistical signifi-
cance of the results was determined by Student’s t-tests
using Microsoft Excel (Microsoft Campus, Redmond,
WA, USA).
Results
BTG1 is induced in response to ionizing radiation
Many tumor suppressor genes are recognized as re-
sponders to ionizing radiation (IR) [32]. To investigate
whether BTG1 functions as a responder to IR, we exam-
ined the protein levels of BTG1 in response to 5 Gy of
X-rays in renal carcinoma 786-O cells by Western blot
analysis. The protein levels of BTG1 were significantly
increased 8 h after irradiation (Figure 1A). We also
treated 786-O cells with DMSO and serum starvation to
investigate whether BTG1 responds to other types of
extracellular stressors and a similar increase in BTG1
levels was observed. Consistent with the results of Western
blotting, qRT-PCR showed that the mRNA levels of BTG1
were increased by more than 2-fold upon treatment with
irradiation (Figure 1B), DMSO (Figure 1C) or serum starva-
tion (Figure 1D). These results indicate that, like other
tumor suppressor genes, BTG1 is up-regulated in response
to X-ray. Meanwhile, the BTG1 can also be induced by
other sources of extracelluar stressors, including the treat-
ments by DMSO and serum starvation.
Tumor cell sensitivity to IR correlates with BTG1 levels
Because BTG1 is involved in the regulation of cell cycle
progression and responds to IR, we examined the effects of
BTG1 expression on the radiosensitivity of renal carcinoma
786-O cells. We transfected 786-O cells with the BTG1 ex-
pression vector pcDNA3.0-BTG1 in order to up-regulate
the protein levels of BTG1. The efficiency of transfection
was confirmed by Western blotting (Figure 2A). The pro-
tein levels of BTG1 increased notably at 24 h after transfec-
tion and lasted for at least three days.
To estimate radiosensitivity, the cell viability was assessed
by trypan blue dye exclusion assay [33]. In this study, trans-
fection of 786-O cells with pcDNA3.0-BTG1 significantly
increased cell viability after radiation exposure (Figure 2B).
To further confirm the effects of BTG1 on radiosensitivity,
we measured the activity of caspase-3 (see Methods)
which is an acknowledged effector among the caspase
family members involved in apoptosis [34]. In order to
more accurately characterize the changes of caspase-3 ac-
tivity among all treatments, we drew standard curve and
tested the caspase-3 activity at 24 h after irradiation
(Additional file 1A and B). At 24 h after exposure to
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Figure 1 BTG1 is induced in response to various extracellular stressors in 786-O cells. (A) Western blot assay of BTG1 at indicated time
points after treatment of human renal carcinoma 786-O cells with 5 Gy of X-rays, DMSO (1.6%, v/v), and serum deprivation. GAPDH is used as a
loading control. Fold changes of protein levels represent the average of three separate blots. (B-D) BTG1 mRNA levels were monitored by
qRT-PCR at 0, 4, and 8 h after treatment of 786-O cells with (B) 5 Gy of X-rays, (C) DMSO (1.6%, v/v) and (D) serum starvation. Values were
normalized to GAPDH. Results represent means ± SE of four independent experiments.
Wu et al. Radiation Oncology 2014, 9:179 Page 4 of 11
http://www.ro-journal.com/content/9/1/1795 Gy of X-rays, compared to transfection of pcDNA3.0,
treatment of 786-O cells with transfection of pcDNA3.0-
BTG1 caused a significant decrease in caspase-3 activation
(Figure 2C). A colony formation assay was performed to
determine the cellular radiation sensitivity. The survival
fraction of 786-O cells transfected with pcDNA3.0-BTG1
without irradiation was significantly lower than that trans-
fected with pcDNA3.0, due to the fact that BTG1 is an
anti-proliferative gene. It is worth noting that there was no
statistically significant difference in the survival fraction of
cells exposed to 5 Gy of X-rays, when the group transfected
pcDNA3.0-BTG1 was compared with the pcDNA3.0 group
(Figure 2D and E). We also used flow cytometry to quantify
changes in the sub-G1 peak at 48 h. The peak of transfec-
tion of BTG1 expression vector was decreased upon expos-
ure to IR compared to the untransfected (Blank) group and
the pcDNA3.0 group (Additional file 1C). These results
suggest that BTG1 expression protects cells from the cyto-
toxic effects of IR.
To further examine the role of BTG1 in radiosensitivity
of 786-O cells, we used siRNA oligonucleotides targeting
BTG1 to specifically knock down BTG1 expression. Transi-
ent transfection of BTG1 siRNA efficiently inhibited BTG1expression in 786-O cells at 24, 48 and 72 h (Figure 3A).
Cell viability assay showed that a treatment with BTG1
siRNA before irradiation promoted the decrease of cell
viability induced by 5 Gy of X-rays (Figure 3B). Caspase-3
activity in cells treated with siRNA against BTG1 was
increased by more than 3-fold as compared with cells
treated with negative control (NC) group (Figure 3C). The
survival fraction was also tested in 786-O cells after expos-
ure to 5 Gy of X-rays. As expected, the colony formation
efficiency of cells transfected with BTG1 siRNA was sig-
nificantly lower than that transfected with its negative
control (Figure 3D and E). Furthermore, transfection with
BTG1 siRNA led to a specific increase in the sub-G1 peak
in 786-O cells at 48 h after IR treatment (Additional
file 1D). These results suggest that down-regulation of
BTG1 significantly increases cellular radiation sensitivity
in 786-O cells.
BTG1 is a direct target of miR-454-3p
To analyze whether BTG1 can be regulated by miRNAs, we
used starBase (sRNA target Base), a miRNA-mRNA inter-
action prediction software consisting of five different algo-
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Figure 2 Tumor cell sensitivity to IR correlates with BTG1 levels. (A) Western blot showing the up-regulation of BTG1 protein in 786-O cells
after transfection with the BTG1 expression vector pcDNA3.0-BTG1 as compared to the control pcDNA3.0 vector and untransfected (blank) cells
after 24, 48 and 72 h. GAPDH is used as loading control. Fold changes of protein levels represent the average of three separate blots. (B) The
trypan blue exclusion assay was used to assess cell viability in 7860-O cells without transfection or after transfection with pcDNA3.0 vector or
pcDNA3.0-BTG1 vector at 48 h after X-ray exposure. (C) The changes of caspase-3 activity of the three group of 786-O cells was analyzed by
caspase-3 activity assay kit at 24 h after X-rays. (D) Survival fractions of cells transfected with the control pcDNA3.0 vector and pcDNA3.0-BTG1
vector in response to 0, 5 Gy of X-rays were measured by colony formation assay. (E) Photographs of colonies formed by 786-O cells after various
treatments. The data (means ± SE) are representative for at least five independent experiments.
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NAs that were predicted to target BTG1 by four or more al-
gorithms for further analysis. These miRNAs included hsa-
mir-130, hsa-mir-301a, hsa-mir-302, hsa-mir-454-3p, and
hsa-mir-19b. Next, we constructed a series of pcDNA3.0
vectors that over-express these miRNAs and screened for
those that regulate endogenous BTG1 levels at 48 h after
transfection in 786-O cells. The BTG1 protein levels in
samples transfected with pcDNA3.0-miR-454-3p displayed
a significant down-regulation (Additional file 2F), indicat-
ing that miR-454-3p can target BTG1. A reproducible re-
pression of endogenous BTG1 protein was also observedfor vectors expressing miR-19b and miR-130, suggesting
the possibility that multiple miRNAs target BTG1.
To determine whether miR-454-3p directly targets BTG1
via its 3′-UTR, the wild type and a mutant of BTG1 3′-
UTR fragment with substitution in the seed region were
synthesized and inserted into a luciferase report system
(Figure 4A). The activity of the wild type reporter was sig-
nificantly reduced by miR-454-3p mimic, whereas the miR-
454-3p mimic had little effect on the mutant of BTG1
3′-UTR construct (Figure 4B). To further validate these find-
ings, endogenous BTG1 levels were assessed in 786-O cells
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Figure 3 Down-regulation of BTG1 significantly increases cellular radiation sensitivity in 786-O cells. (A) The down-regulation of endogenous
BTG1 protein following transfection with siRNA oligonucleotides against BTG1 (siRNA-BTG1) or nonsense small RNA oligonucleotides (negative control,
NC) were compared to untransfected (blank) cells. GAPDH serves as loading control. Fold changes of protein levels represent the average of three
separate blots. (B) The percentage of 786-O cell viability after transfection with siRNA oligonucleotides against BTG1 (siRNA-BTG1) or nonsense small
RNA oligonucleotides (negative control, NC) was determined by trypan blue dye exclusion assay at 48 h after X-ray exposure. (C) Effects of nonsense
small RNA oligonucleotides or siRNA-BTG1 over-expression on caspase-3 activity in 786-O cells without irradiation or with 5 Gy of X-rays. (D) Colony
formation assay of 786-O cells transfected with NC or siRNA-BTG1. (E) Representative plates of survival fraction of 786-O cells after various treatments.
The data (means ± SE) are representative for at least five independent experiments.
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mRNA levels at 48 h post-transfection (Figure 4C and D).
These results confirm that BTG1 is a target of miR-454-3p.
To determine whether endogenous miR-454-3p levels are
regulated physiologically by IR, we assessed miR-454-3p ex-
pression in 786-O cells over a timecourse of exposure to
5 Gy of X-rays. While BTG1 mRNA levels increased, miR-
454-3p levels decreased upon treatment (Figure 4E). It is
worth noting that the BTG1 mRNA level decreased at 16 h
after irradiation, whereas the miR-454-3p level increased.
The miR-454-3p gene is located in the first intron of the
host gene, SKA2 (spindle and kinetochore-associatedprotein 2), which plays a critical role in proper mitotic
progression, checkpoint silencing, and timely anaphase
onset [36]. To test whether the expression of SKA2 corre-
lates with that of miR-454-3p, SKA2 mRNA was quanti-
fied by qRT-PCR. Similar to the results for miR-454-3p,
the expression of SKA2 was down-regulated in 786-O cells
after IR (Figure 4F), providing further verification of our
findings. These results indicate that miR-454-3p regulates
the expression of BTG1 through a direct interaction with
the 3′-UTR of the BTG1, and that a decrease in its ex-
pression correlates with BTG1 up-regulation during IR































































































































Figure 4 MiR-454-3p negatively regulates BTG1 expression. (A) Construction of a vector with either the wild-type sequence of the miR-454-
3p binding site within the 3′-UTR of BTG1 (Wt BTG1 3′-UTR) or a mutated seed sequence (Mut BTG1 3′-UTR). The black box shows the predicted
miR-454-3p binding site. The seed sequence is shown in red. (B) Luciferase reporter assay results are shown at 48 h following co-transfection of
786-O cells with the Wt BTG1 or Mut BTG1 vectors together with miR-454-3p mimic (miR-454-3p) or nonsense small RNA oligonucleotides
(negative control, NC). Results (means ± SE) are representative for three independent experiments. (C) Western blotting was performed at 48 h
after transfection with miR-454-3p or NC oligonucleotides. GAPDH was used as loading control. Fold changes of protein levels represent the
average of three separate blots. (D) BTG1 expression is regulated by miR-454-3p at the mRNA level. QRT-PCR was conducted to quantify the
expression level of BTG1 mRNA at 48 h after 786-O cells were transfected with miR-454-3p or NC oligonucleotides. (E) MiR-454-3p and BTG1
mRNA levels were monitored by qRT-PCR at the indicated time points after irradiation with 5 Gy of X-rays. U6 and GAPDH were used as controls.
(F) SKA2 mRNA levels were monitored by qRT-PCR at the indicated times after irradiation with 5 Gy of X-rays. GAPDH was used as a control.
The data (means ± SE) are representative for at least four independent experiments with similar results.
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sensitivity to IR and relieves the G2/M arrest induced by
IR in 786-O cells
Our results thus far suggest that down-regulation of BTG1
can enhance the radiosensitivity of 786-O cells and thatBTG1 is also a target of miR-454-3p. Consequently, we pos-
tulated that miR-454-3p may affect cell radiosensitivity. To
assess the effects of miR-454-3p on radiosensitivity, we ex-
posed 786-O cells to 5 Gy of X-rays following transfection
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Figure 5 (See legend on next page.)
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Figure 5 MiR-454-3p enhances apoptosis and affects the G2/M arrest induced by IR. (A) The percentage of cell viability of 786-O cells at
48 h after transfection of nonsense control siRNA (negative control, NC) or miR-454-3p mimic (miR-454-3p) was calculated by trypan blue dye
exclusion assay with or without exposure to X-rays (48 h after exposure to X-ray). (B) The activation of caspase-3 were tested at 24 h in 786-O
cells after transfection with nonsense control siRNA (negative control, NC) or miR-454-3p mimic (miR-454-3p) with or without exposure to X-ray
(24 h after exposure to X-ray). (C) The effect of transfection with miR-454-3p mimic on clonogenicity of 786-O cells was characterized by colony
formation assay. (D) Photographs of the colony formation of 786-O cells after various treatments. (E and F) 786-O cells were transfected with the
pcDNA3.0 vector or pcDNA3.0-BTG1 vector for 48 h were analyzed for cell cycle kinetics (E) without irradiation (0 Gy of X-rays) or (F) with
irradiation with 5 Gy of X-rays (5 Gy of X-rays). (G and H) 786-O cells transfected with control siRNA (NC), siRNA oligonucleotides against BTG1
(siRNA-BTG1), or miR-454-3p mimic (miR-454-3p) for 48 h were analyzed for cell cycle kinetics (G) without irradiation (0 Gy of X-rays) or (H) with
irradiation with 5 Gy of X-rays (5 Gy of X-rays). The percentage of total cells at G0/G1, S, and G2/M phases were determined. The data
(means ± SE) are representative for at least five independent experiments.
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relative to the NC group was reduced by 20% (Figure 5A).
Similarly, over-expression of miR-454-3p mimic was associ-
ated with more than 4-fold increase of caspase-3 activity at
24 h (Figure 5B). Clonogenicity of 786-O cells transfected
with miR-454-3p mimic was significantly reduced after ex-
posure to 5 Gy of X-rays (Figure 5C and D). The sub-G1
percentage increased evidently at 48 h as assessed by flow
cytometry (Additional file 1E), indicating that miR-454-3p
enhances IR-mediated apoptosis.
Because cell cycle control is intimately involved in the in-
duction of apoptosis during IR, we also examined whether
BTG1 can regulate the cell cycle. 786-O cells were trans-
fected with control pcDNA3.0 vector or pcDNA3.0-BTG1
expression vector, and the effects of IR on the cell cycle
distribution were assessed by flow cytometry after 48 h.
The majority of the cells were in the G1 phase prior to IR
treatment. Exposure to 5 Gy of X-rays caused a strong G2/
M arrest for cells transfected with control pcDNA3.0
vector (Figure 5E and F). Whereas, cells transfected
with pcDNA3.0-BTG1 were resistant to IR-induced G2/
M phase arrest after exposure to 5 Gy of X-rays. These
results indicate that high levels of BTG1 can inhibit IR-
induced G2/M arrest.
To further understand the role of BTG1 in inhibiting
IR-induced G2/M arrest and to assess the effects of miR-
454-3p on cell cycle arrest, 786-O cells were transfected
with either siRNA oligonucleotides against BTG1 or miR-
454-3p mimic. Flow cytometry analysis showed that BTG1
siRNA and miR-454-3p had no significant effect on cell
cycle distribution in the absence of irradiation (Figure 5G).
Surprisingly, however, BTG1 siRNA and miR-454-3p
mimic promoted an IR-induced S phase arrest and abol-
ished the G2/M arrest in 786-O cells exposed to 5 Gy of
X-rays (Figure 5H). These results indicate that over-
expression of BTG1 overcomes the G2/M arrest induced
by IR, but knockdown of BTG1 expression causes a switch
of the arrest from the G2/M phase to the S phase. One
can easily conjecture about that down-regulation of BTG1
would impede the activation of the G1 checkpoint and
lead to damage accumulation during S phase and the con-
sequent triggering of the S phase arrest.Discussion
In the present study, we identified miR-454-3p as regulator
of BTG1 expression based on bioinfomatic software pre-
diction and detailed experimental validation. The expres-
sion of BTG1 and miR-454-3p was shown to inversely
correlate in 786-O cells upon exposure to environmental
stressors, thus supporting a physiological role for miR-454-
3p in regulating BTG1 expression. In addition to miR-454-
3p, miR-19b was predicted to have two binding sites on
the 3′-UTR of the BTG1 mRNA, one of which occupies
the same site as the putative miR-454-3p target. A sig-
nificant repression of endogenous BTG1 protein by
miR-19b expression vector was also observed in 786-O
cells (Additional file 2F). Therefore, we speculate that
more than one miRNA may target BTG1, and these
miRNAs may function antagonistically under specific
physiological conditions. Future experimentation to ad-
dress this possibility may unveil a regulation network of
BTG1 regulation by miRNAs.
Our results show that the expression of SKA2 is regu-
lated coordinately with the expression of miR-454-3p.
Interestingly, miR-454-3p and a third putative BTG1 tar-
get, miR-301a, are encoded within the first intron of
SKA2, whose depletion affects the cell cycle by inducing a
metaphase-like delay [37]. MiR-301a also down-regulates
the expression of an inhibitor of NF-κB, Nkrf [38]. NF-κB
binds directly to the SKA2 promoter region to activate the
transcription of SKA2 and miR-301a and also enhances
persistent NF-κB activation to facilitate tumor growth
[37,39], thus suggesting a feedback loop to moderate
SKA2 function. It is intriguing that miR-454-3p targets
BTG1, which has a strong anti-proliferative ability, and
suggesting an additional complexity of the growth regula-
tory function derived from the SKA2 locus. BTG1 has
been suggested to inhibit NF-κB activities [40]. Therefore,
complex regulatory loop appears to regulate cell growth
inhibition by BTG1, and it is likely that SKA2, NF-κB and
multiple miRNAs are coordinated to control the BTG1
expression.
Little is known about the molecular mechanisms of
control of the cell cycle by BTG1, and most of the infor-
mation comes from interaction studies. BTG1 exerts
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http://www.ro-journal.com/content/9/1/179cellular functions by interacting with PRMT1, HOXB9,
and hCAF1, which regulate the expression of a number
of genes involved in cell cycle control and progression
[41-43]. CCNA2 (cyclinA2) physically associates with
BTG1 [44] and controls S phase by activating CDK2 ki-
nases to initiate DNA synthesis [45]. Ectopic over-
expression of CCNA2 triggers checkpoint response and
subsequently increases the S phase population in mam-
malian cells [45]. We found that siRNA-mediated silen-
cing of BTG1 led to S phase arrest after IR. Additionally,
the S phase arrest can also be mediated by miR-454-3p.
Furthermore, miR-454-3p is highly expressed in the S
phase. The above negative regulation may suggest the
association between CCNA2 and BTG1 in the control of
the cell cycle progression of S phase. However, our re-
sults also show that over-expression of BTG1 in 786-O
cells promotes a G1 arrest. Therefore, the link between
miR-454-3p, BTG1 and cell cycle is likely complex and
warrants further investigation to unravel the network of
cell cycle regulators that are functionally associated with
BTG1.
Conclusions
In conclusion, our study reveals that BTG1 is a direct
target of miR-454-3p. Changes of its expression levels
render tumor cells sensitive to radiation due to the role
of BTG1 in cell cycle progression. Therefore, down-
regulation of BTG1 via miR-454-3p presents a possible
strategy to sensitize tumor cells to radiotherapy.
Additional files
Additional file 1: (A) The graph represents the caspase-3 colorimetric
calibration, which were measured with an ELISA reader at an
absorbance of 405 nm (Caspase-3 colorimetric calibration). Results are
representative for three independent experiments. (B) The dynamic of
caspase-3 activity was tested in 786-O cells without transfection after
exposure to 5 Gy of X-rays (Activation of caspase-3 by X-ray). Results are
representative for three independent experiments. (C, D and E) The sub-G1
percentage of all the treatments of 786-O cells were analyzed by flow
cytometry 48 h after X-ray exposure. Results are representative for five
independent experiments.
Additional file 2: (F) Western blot showing the protein levels of
BTG1 in 786-O cells 48 h after transfection with pcDNA3.0 miRNA
vectors. GAPDH is shown as loading control. Fold changes of
protein levels represent the average of three separate blots.
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